Author: admin

  • Chubb Appoints Jimaan Sané to Head of Growth, Global Cyber

    Chubb Appoints Jimaan Sané to Head of Growth, Global Cyber

    Zurich, January 7, 2026 – Chubb today announced that Jimaan Sané has been appointed Head of Growth, Global Cyber, effective immediately.

    In his new role, Jimaan will oversee the performance and expansion of Chubb’s global cyber growth strategies. Collaborating closely with global distribution and underwriting teams, he will be responsible for delivering Chubb’s premier cyber solutions to clients and brokers across all industry segments and business sizes.

    “Jimaan is a highly accomplished leader with a proven track record in driving global cyber growth initiatives,” said Mike Kessler, Vice President, Chubb Group and Division President, Global Cyber Risk. “We are confident that his innovative approach will further enhance our best-in-class cyber solutions and strengthen our position as a leader in the cyber insurance market.”

    Jimaan joins Chubb from Beazley Group, where he held a variety of leadership roles in Cyber Risks for over a decade. Most recently, he served as Growth Leader for London and International, overseeing strategy and growth initiatives across London wholesale and international platforms. Jimaan brings extensive experience managing multinational underwriting teams across London, Europe, Canada and Singapore.

    About Chubb

    Chubb is a world leader in insurance. With operations in 54 countries and territories, Chubb provides commercial and personal property and casualty insurance, personal accident and supplemental health insurance, reinsurance and life insurance to a diverse group of clients. The company is defined by its extensive product and service offerings, broad distribution capabilities, exceptional financial strength and local operations globally. Parent company Chubb Limited is listed on the New York Stock Exchange (NYSE: CB) and is a component of the S&P 500 index. Chubb employs approximately 43,000 people worldwide. Additional information can be found at: www.chubb.com.

    Media Contact

    mediarelations@chubb.com

    Continue Reading

  • Foreign Ministry Spokesperson Mao Ning’s Regular Press Conference on January 7, 2026_Ministry of Foreign Affairs of the People’s Republic of China

    CCTV: What is the special significance of Chinese Foreign Minister’s visit to Africa on the first overseas trip of this year? What does China hope to achieve through this trip?

    Mao Ning: This year marks the 70th anniversary of the start of…

    Continue Reading

  • Comparative Outcomes of Early Surgical Intervention Versus Nonoperative Management in Adhesive Small Bowel Obstruction

    Comparative Outcomes of Early Surgical Intervention Versus Nonoperative Management in Adhesive Small Bowel Obstruction

    Continue Reading

  • Yemen separatist leader accused of treason as Saudis strike forces

    Yemen separatist leader accused of treason as Saudis strike forces

    The Saudi-backed presidential council in Yemen has expelled the leader of a separatist group and charged him with treason after he failed to fly to Riyadh for talks.

    Six other members of the presidency accused Aidarous al-Zubaidi, head of the…

    Continue Reading

  • Yemen separatist leader accused of treason as Saudis strike forces

    Yemen separatist leader accused of treason as Saudis strike forces

    In December, the STC’s forces launched offensives to seize the eastern provinces of Hadramawt and al-Mahra from the government, saying they were necessary to “restore stability” in the south and combat the Houthis, al-Qaeda and Islamic State…

    Continue Reading

  • McMaster discovery could lead to new treatments for drug-resistant fungal infections

    McMaster discovery could lead to new treatments for drug-resistant fungal infections















    McMaster discovery could lead to new treatments for drug-resistant fungal infections – Faculty of Health Sciences


















    Continue Reading

  • Samsung Makes Enterprise Debut at CES 2026 with Spatial Signage – Samsung Newsroom U.K.

    Samsung Makes Enterprise Debut at CES 2026 with Spatial Signage – Samsung Newsroom U.K.

     

    Samsung Electronics, a global leader in technology, today announced that Spatial Signage has been recognized by the Consumer Technology Association (CTA)® as part of the CES Innovation Awards…

    Continue Reading

  • Researchers Raise Concerns about Faster Aging, Possible Early-Onset Dementia, for Children and Young Adult Cancer Survivors

    Researchers Raise Concerns about Faster Aging, Possible Early-Onset Dementia, for Children and Young Adult Cancer Survivors

    Adolescent and young adult cancer survivors age faster than their peers who did not have cancer, according to a new study, which also describes how accelerated aging occurs both at the cellular level and in brain function, such as memory,…

    Continue Reading

  • Is ‘Open Stone Surgery with Intraoperative Nephroscopy’ a better alter

    Is ‘Open Stone Surgery with Intraoperative Nephroscopy’ a better alter

    Introduction

    The global incidence and prevalence of urolithiasis are steadily rising, creating a need for safe, effective, and affordable treatment options.1 This worldwide trend is now nearly the same in both developing and developed countries.

    Continue Reading

  • Intellia Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

    Intellia Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

    CAMBRIDGE, Mass., Jan. 07, 2026 (GLOBE NEWSWIRE) — Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that the company will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, January 14, 2026 at 9:00 a.m. PT.

    A live webcast will be available on the Events and Presentations page in the Investors & Media section of Intellia’s website, www.intelliatx.com. A replay of the webcast will be available on Intellia’s website for approximately 30 days.

    About Intellia Therapeutics
    Intellia Therapeutics, Inc. (NASDAQ:NTLA) is a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies. Since its inception, Intellia has focused on leveraging gene editing technology to develop novel, first-in-class medicines that address important unmet medical needs and advance the treatment paradigm for patients. Intellia’s deep scientific, technical and clinical development experience, along with its people, is helping set the standard for a new class of medicine. To harness the full potential of gene editing, Intellia continues to expand the capabilities of its CRISPR-based platform with novel editing and delivery technologies. Learn more at intelliatx.com and follow us @intelliatx.

    Intellia Contacts:

    Investors:Jason FredetteVice President, Investor Relations and Corporate Communications
    Intellia Therapeutics, Inc.
    jason.fredette@intelliatx.com

    Media:Matt CrensonTen Bridge Communications
    media@intelliatx.com  
    mcrenson@tenbridgecommunications.com

    Primary Logo

    Source: Intellia Therapeutics, Inc.

    Continue Reading